Connecticut's Department of Consumer Protection (DCP) today announced that new preliminary data shows combined sales for adult-use cannabis and medical marijuana totaled nearly $25 million for the period from August 1, 2023 to August 31, 2023.
The adult-use market recorded more than $14 million in sales during the month of August, while the medical marijuana market recorded almost $11 million in sales for the same period. Adult-use sales began on Jan. 10, 2023.
In August, medical marijuana patients purchased 278,395 products, and adult-use consumers purchased 354,700 products. The average product price for medical marijuana patients was $39.36 in August, while the average price of adult-use products was $39.49.
In August, 52 percent of sales were usable cannabis, or flower, while vapes made up 30 percent of sales. Edible products represented 11 percent of sales.
The data was collected through the state’s seed-to-sale tracking system. DCP does not make revenue projections, set sales expectations, collect taxes or regulate prices.
The preliminary data does not include taxes collected at the point of sale on adult-use transactions and is subject to further review by the department. Medical marijuana patients do not pay taxes on the purchase of their medicine.
Sales data for the medical marijuana market is not available prior to Jan. 10, 2023. Seed-to-sale tracking was not previously required for medical marijuana sales. Adult-use and medical marijuana sales are now recorded in BioTrack, the inventory tracking system used to monitor the movement of cannabis in the state’s medical and adult-use cannabis markets.
Transaction limits of 1/4 ounce of raw flower or the equivalent remain in effect for all adult-use purchases. Medical marijuana patients may purchase up to 5 ounces per month and are not subject to individual transaction limits.
Cannabis was approved for adult-use in June 2021. Adult-use sales began Jan. 10, 2023 at licensed retailers.